Plants have emerged in the past decade as a suitable alternative to the current production systems for recombinant pharmaceutical proteins and, today their potential for low-cost production of high quality, much safer and biologically active mammalian proteins is largely documented.
Among various plant expression systems being explored, genetically modified suspension-cultured plant cells offer a promising system for production of biopharmaceuticals. Indeed, when compared to other plant-based production platforms that have been explored, suspension-cultured plant cells have the advantage of being totally devoid of problems associated with the vagaries of weather, pest, soil and gene flow in the environment. Because of short growth cycles, the timescale needed for the production of recombinant proteins in plant cell culture can be counted in days or weeks after transformation compared to months needed for the production in transgenic plants. Moreover, recovery and purification of recombinant proteins from plant biomass is an expensive and technically challenging business that may amount to 80–94% of the final product cost. One additional advantage of plant cell culture is that the recombinant protein fused with a signal sequence can be expressed and secreted into the culture medium, and therefore recovered and purified in the absence of large quantities of contaminating proteins. Consequently, the downstream processing of proteins extracted from plant cell culture medium is less expensive, which may/does balance the higher costs of fermentation. When needed for clinical use, recombinant proteins are easily produced in suspension-cultured plant cells under certified, controllable and sterile conditions that offer improved safety and provide advantages for good manufacturing practices and regulatory compliance. In this chapter, we present basic protocols for rapid generation of transgenic suspension-cultured cells of Nicotiana tabacum, Oriza sativa and Arabidopis thaliana. These systems are powerful tools for plant-made pharmaceuticals production in highly controlled conditions.
活性氮(RNS)是巨噬細胞在稱為氧化爆發的過程中響應病原體而產生的一組殺菌分子。一氧化氮(NO)是由精氨酸通過誘導的一氧化氮合酶(iNOS)產生的RNS的成員。刺激后巨噬細胞產生iNOS的活性和NO是......
粒細胞-巨噬細胞集落刺激因子(granulocyte-macrophagecolony-stimulatingfactor,GM-CSF)主要由T細胞和巨噬細胞產生,能夠誘導粒細胞前體和巨噬細胞前體細......
艾美捷牛粒細胞-巨噬細胞集落刺激因子/BovineGM-CSF重組蛋白中文說明書:目錄編號(規格):RP0871B-005(5μg)RP0871B-025(25μg)RP0871B-100(100μg......
粒細胞-巨噬細胞集落刺激因子(GM-CSF)是由巨噬細胞、T細胞、肥大細胞、NK細胞、內皮細胞和成纖維細胞分泌的蛋白質。GM-CSF刺激干細胞產生粒細胞(中性粒細胞,嗜酸性粒細胞和嗜堿性粒細胞)和單核......